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BACKGROUND: Sustained viral response (SVR) improves survival for patients with hepatitis C (HCV) and hepatocellular carcinoma
(HCC) after curative treatment; however, the benefit of SVR in those with active HCC with a significant competing risk of mortality is
unknown. This study aimed to evaluate the association between SVR and outcomes in patients with active HCC. METHODS: The authors
performed a multicenter, retrospective cohort study including consecutive adults with HCV cirrhosis and treatment-naive HCC diagnosed between 2014 and 2018. Patients were stratified into two groups: active viremia (n = 431) and SVR before HCC diagnosis (n = 135).
All patients underwent nonsurgical therapy as their initial treatment and were followed until liver transplantation, last follow-up, or death.
The primary outcome was incident or worsening hepatic decompensation within 6 months and the secondary outcome was overall survival. All analyses used inverse probability of treatment weights (IPTW) to account for differences between the nonrandomized cohorts.
RESULTS: Post-SVR patients had significantly lower odds of hepatic decompensation compared to viremic patients (odds ratio [OR],
0.18; 95% confidence interval [CI], 0.06–0.59). Results were consistent among subgroups of patients with Child Pugh A cirrhosis (OR,
0.22; 95% CI, 0.04–0.77), Barcelona Clinic Liver Cancer stage B/C HCC (OR, 0.20; 95% CI, 0.04–0.65), and those receiving nonablative
HCC therapies (OR, 0.21; 95% CI, 0.07–0.67). However, in IPTW multivariable Cox regression, SVR was not associated with improved
survival (hazard ratio, 0.79; 95% CI, 0.56–1.12). CONCLUSIONS: Patients with HCV-related HCC and SVR are less likely to experience
hepatic decompensation than viremic patients, suggesting patients with HCC who are undergoing nonsurgical therapies may benefit
from DAA treatment. Cancer 2022;0:1-9. © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer
Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits
use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
KEYWORDS: DAA, decompensation, HCC, HCV, SVR.

INTRODUCTION
Chronic hepatitis C (HCV) remains a leading cause of chronic liver disease and hepatocellular carcinoma (HCC) worldwide accounting for nearly 20,000 deaths annually in the United States.1 Chronic HCV infection leads to progressive
fibrosis that can result in cirrhosis and its associated complications. Despite recommendations for universal screening for
HCV and availability of highly effective direct acting antivirals (DAAs) for the treatment of HCV, there remains a reservoir of patients with untreated HCV who present with cirrhosis and HCC.2,3
Treatment of HCV forestalls fibrosis progression, decreases HCC risk, and can improve patient reported outcomes
in patients with cirrhosis.4–6 DAA therapy has been shown to be highly efficacious with near universal cure rates, even
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in patients with a history of HCC.7,8 We have previously
shown DAA therapy after complete HCC response is not
associated with increased risk of HCC recurrence and is
in fact associated with improved overall survival, mediated through sustained virological response (SVR).9,10
However, the benefits of DAA therapy in patients
with active HCC remain unclear, and practice patterns
regarding treatment vary widely.11,12 Prior analyses estimating the benefit of HCV therapy in active HCC
have focused on early-stage patients undergoing surgical
therapy, with few data in patients with intermediate-or
advanced-stage disease.13 These more advanced-stage patients have a substantial competing risk of mortality from
HCC, and whether treatment of the HCV is indicated is
unclear. Furthermore, with approval of more efficacious
systemic therapies for advanced-stage HCC, the question
of whether patients benefit from HCV treatment at the
time of HCC diagnosis is increasingly salient, particularly
in patients with a high competing risk of mortality from
HCC.14 Furthermore, deterioration in liver function is
a major cause of lack of eligibility for treatment with
systemic or locoregional HCC therapies.15 We aimed to
compare the association between SVR and hepatic decompensation and overall survival in patients with HCC
undergoing nonsurgical therapies.
MATERIALS AND METHODS
Design

We performed a multicenter retrospective cohort study
at nine US centers from the North American Liver
Cancer (NALC) Consortium, including consecutive patients with HCV-related HCC from January 2014 to
June 2018. We included adult (18+ years old) patients
with a documented history of HCV RNA positivity who
had treatment-naive HCC diagnosis per the American
Association for the Study of Liver Diseases guidelines
(i.e., histologic confirmation or lesions >1 cm with characteristic appearance on imaging [arterial enhancement
and delayed washout]). Because most patients who receive
surgical HCC therapy are treated for HCV after surgery,
we only included patients whose first HCC treatment was
nonsurgical in nature: local ablation, transarterial chemoembolization (TACE), transarterial radioembolization
(TARE), stereotactic body radiation therapy (SBRT), or
systemic therapy. We also excluded patients who were
lost to follow-up within 3 months of HCC diagnosis,
those that lacked complete laboratory components of
the Child-Turcotte-Pugh (CTP) score within 12 months
of diagnosis, or those with a history of other active
2

malignancy during study period (except for nonmelanoma skin cancer) (Fig. S1). We excluded patients with
SVR from interferon-based therapies. The cohort was
split into two groups: (1) those with active HCV viremia
at the time of HCC diagnosis, and (2) those who had
achieved SVR before HCC diagnosis. The Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines for observational studies were used
for this study (Supporting information).16 Institutional
review board approval was obtained at all sites involved
in this study and de-identified data were transferred to
the University of Michigan through data use agreements.
Outcomes

Our primary outcome was new or worsening hepatic decompensation within 6 months of HCC diagnosis. We
defined new hepatic decompensation as new onset ascites
requiring diuretics or paracentesis, new onset hepatic
encephalopathy (HE) requiring lactulose and/or rifaximin, new onset variceal bleeding documented on upper
endoscopy, or increase in Child Pugh score ≥ 2 points
from time of HCC diagnosis. We defined worsening
decompensation as ascites newly requiring paracentesis,
hepatic encephalopathy requiring hospitalization despite
lactulose compliance, addition of rifaximin to an existing
regimen of lactulose, or increase in Child Pugh score ≥ 2
points. We performed sensitivity analyses with different
time points for development of decompensation (3 and
9 months). Patients were censored at the time of death or
liver transplantation. Our secondary outcome was overall
survival measured from time of HCC diagnosis (defined
as time 0). Patients with active viremia at time of HCC
diagnosis were censored at initiation of DAA therapy that
led to SVR.
Data collection

We used a standardized data collection template to
obtain demographic and clinical variables at HCC
presentation from electronic medical records at each
site, including age, sex, race, ethnicity, platelet count,
aspartate aminotransferase, alanine aminotransferase,
HCV viral load, HCV genotype, Eastern Cooperative
Oncology Group performance status, and α-fetoprotein
(AFP). In HCV-treated patients, we collected DAA regimen and time from HCC diagnosis to DAA initiation.
Degree of liver dysfunction was assessed by Child-Pugh
and Model for End-Stage Liver Disease scores and presence and severity of hepatic decompensation. Tumor
burden, as determined by interpretation of imaging by
local radiologists at each site, was categorized according
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to Barcelona Liver Cancer Classification (BCLC) staging. We recorded the number and type of HCC treatments with subsequent tumor response. We recorded
liver function and presence of hepatic decompensation at 3, 6, 9, and 12 months after HCC diagnosis.
Data was collected until death, last follow-up, or liver
transplantation.
Analytic plan

To account for the nonrandomized nature of the data,
we performed inverse probability of treatment weighted
(IPTW) analyses when comparing outcomes between
groups. Patient-level weights were calculated as the inverse of the probability of receiving the observed treatment. The probability (propensity) of treatment was
estimated from logistic regression models including all
variables thought to possibly be associated with treatment assignment and/or outcome. Two such models
were developed; one using all relevant covariates and the
other excluding variables related to liver function. We
performed the latter model given DAA therapy could
influence liver function, and adjusting for liver function at time of HCC treatment may capture some of
DAA treatment effect on post-HCC outcomes. Hepatic
decompensation was summarized as binomial proportions and compared between groups using logistic regression models also adjusting for other covariates and
both using IPTWs. We also included a subject-level random intercept to account for possible between-patient,
within-
center, correlation. Our primary interest was
centered on comparing outcomes between the viremic
and SVR HCC cohorts; we also performed a post hoc
subgroup analysis comparing outcomes between DAA-
exposed and DAA-naive viremic patients. A key secondary end point was overall survival (OS) calculated as
the time from HCC treatment to death from any cause
with censoring at the earliest of last follow-up or liver
transplantation. OS was compared between the cohorts
using log-rank tests and score tests in Cox models with
center level frailty (random effect) and other potential
confounding variables. All analyses were conducted
using SAS software, Version 9 (SAS).
RESULTS
Patient characteristics

In total, there were 135 patients in the SVR-HCC group
and 431 patients in the viremic-HCC group with their
baseline characteristics shown in Table 1. Compared
to the viremic-HCC group, patients in the SVR-HCC
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group were older, had a higher proportion of females,
and higher proportion of non-Hispanic White patients.
Patients in the SVR-HCC group also had earlier stage
disease, with a higher proportion having BCLC stage
0/A (59.6% vs. 45.7%), smaller median maximum
tumor diameter (2.6 vs. 3.2), and less vascular invasion (11.0% vs. 18.3%) or extrahepatic disease (5.9%
vs. 10.2%). Hepatic decompensation at baseline was
present in approximately one-third of the cohort, with
the viremic-HCC group having a higher prevalence of
ascites (33.9% vs. 27.4%) and the SVR-HCC group
having a higher prevalence of hepatic encephalopathy (24.4% vs. 19.9%). The viremic-HCC group and
SVR-HCC groups had similar median MELD scores
(10 vs. 9). The characteristics of the cohorts after IPTW
weighting are shown in Table 1, which showed balanced
cohorts without significant differences between the
groups.
For patients in the SVR-HCC group, the median
time from initiation of DAA therapy to HCC diagnosis
was 17.7 months (interquartile range [IQR], 8–28). For
the viremic cohort, 27.3% of patients were treated with
DAAs on follow-up, a median of 14.5 months (IQR, 9.5–
19) from HCC diagnosis. The median follow-up time
after HCC diagnosis of the entire cohort was 29 months
(27 months in the SVR-
HCC and 30 months in the
viremic-HCC group). Median time from HCC diagnosis
to the first cancer treatment was 55 days (IQR, 42–81)
in the SVR-HCC group versus 58 days (IQR, 36–94) in
the viremic-HCC group (p = .58). The most common
initial therapies were TACE (51.2%) followed by ablation (13.1%) and systemic therapy (9.0%). The median
number of total therapies received was two (IQR, 1–3) in
the SVR-HCC group versus two (IQR, 1–3) the viremic-
HCC group. At the end of the observed follow-up, 42%
of patients had died (45% in viremic-HCC vs. 31% in
SVR-HCC) and 11% had undergone liver transplantation (13% in viremic-HCC vs. 6% in SVR-HCC).
Hepatic decompensation

In IPTW analysis, patients with SVR-HCC had significantly less hepatic decompensation than patients with
viremic-HCC, with the incidence of new or worsening
hepatic decompensation detailed in Figure 1 (log-rank
p < .001). Kaplan–Meier estimates of the proportion of
patients with clinical decompensation or an increase in
CTP score ≥ 2 within 6 months after HCC diagnosis are
7% of the SVR-HCC group and 23% of the viremic-
HCC group. The most common new or worsening decompensation was ascites (9%), followed by HE (4%),
3
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TABLE 1. Baseline characteristics of patients at the time of HCC diagnosis before and after IPTW
Baseline cohort

Age (mean ± SD), y
Male sex % (n)
Race % (n)
White
Black
Asian
Other
Unknown
Ethnicity % Hispanic (n)
BCLC class % (n)
0/A
B
C/D
Tumor no. % (n)
1
2
3+
Diameter of largest tumor,
median (IQR)
Vascular invasion %
Distant metastases %
ECOG, median (IQR)
Child Pugh % A/B/C
MELD, median
Median AFP (IQR)
Median platelet count (IQR)
Hepatic encephalopathy % (n)
Ascites % (n)
No. of HCC therapies (IQR)
Initial HCC therapy % (n)
TACE
Ablation
TARE
Systemic
SBRT
Other

After IPTW weighting

Viremic HCC (n = 431)

Post SVR HCC (n = 135)

Viremic HCC

Post SVR HCC

60.9 ± 6.3
81.6 (510)

64.1 ± 6.4
75.4 (141)

62 (7.2)
78

62 (6.2)
76

57 (245)
26 (114)
2 (11)
9 (40)
5 (22)
14.4 (90)

62 (117)
25 (34)
3 (4)
4 (5)
6 (8)
10.6 (20)

58
26
3
8
5
12

58
25
4
8
6
13

42.9 (268)
26.7 (167)
27.0 (169)

57.2 (107)
19.2 (36)
19.7 (37)

49
29
22

51
28
20

58.5 (364)
24.9 (155)
16.5 (103)
3.2 (2.9, 3.5)

72.4 (136)
19.7 (37)
8.0 (15)
2.6 (2.2, 3.0)

60
27
13
3.1 (2.3, 4.8)

64
27
9
3.0 (2.1, 4.6)

18.3 (79)
14.2 (61)
0 (0,1)
55/38/7
10
28 (5, 3190)
103 (51, 256)
20.2 (126)
37.0 (231)
2 (1, 3)

11.1 (15)
8.9 (12)
0 (0,1)
67/27/6
9
9 (3, 1230)
107.5 (49, 218)
29.4 (55)
31.0 (58)
2 (1, 3)

16
9
0 (0–1)
57/37/7
10 (8–12)
20 (8–114)
100 (71–159)
20.1
33.1
2 (1, 3)

14
8
0 (0–1)
66/27/7
10 (8–12)
16 (5–169)
104 (74–153)
25.2
26.9
2 (1, 3)

52.9 (228)
10.7 (46)
9.5 (41)
9.3 (40)
8.3 (36)
9.3 (40)

45.9 (62)
20.7 (28)
8.8 (12)
8.9 (12)
8.1 (11)
7.4 (10)

51.1
13.2
9.3
9.1
8.0
8.6

48.9
14.3
9.0
9.1
8.4
8.2

Abbreviations: AFP, α-fetoprotein; BCLC, Barcelona Cancer Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; IPTW,
inverse probability of treatment weights; IQR, interquartile range; MELD, Model For End-Stage Liver Disease; SBRT, stereotactic body radiation therapy; SVR,
sustained virological response; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.

and variceal bleeding (1%), with no difference in pattern
of hepatic decompensation between the two groups. In
IPTW logistic regression analysis examining decompensation at a fixed time point of 6 months from diagnosis,
adjusted for baseline CP and first HCC treatment as covariates, SVR-HCC patients had a lower adjusted risk
of decompensation compared to viremic-HCC patients
(OR, 0.18; 95% CI, 0.06–0.59). Results were similar in
a subgroup analysis excluding patients who underwent
local ablation as initial therapy (OR, 0.21; 95% CI,
0.07–0.57). In sensitivity analyses, a lower risk of hepatic
decompensation continued to be observed in the SVR-
HCC group at 3 months (OR, 0.41; 95% CI, 0.19–0.82)
and 9 months (OR, 0.46; 95% CI, 0.20–0.93).

4

Overall survival

Median survival from HCC diagnosis for the SVR-
HCC group was 49 (95% CI, 26, not reached) months
whereas the viremic-HCC group had a median survival
of 34 months (95% CI, 29–40). The IPTW Kaplan–
Meier estimates of survival from diagnosis were similar
between the two cohorts (hazard ratio [HR], 0.75; 95%
CI, 0.53–1.07; log-rank test p = .21) (Fig. 2). In the
IPTW Cox multivariable model, OS was not significantly different in the viremic and SVR-HCC group;
(adjusted HR, 0.79; 95% CI, 0.56–1.12). Results were
similar in a sensitivity analysis excluding patients who
underwent local ablation as initial therapy (HR, 0.77;
95% CI, 0.52–1.14).
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Figure 1. Kaplan–Meier curve of time to decompensation for the inverse probability of treatment weighted cohort.

Figure 2. Kaplan–Meier curve of overall survival for the inverse probability of treatment weighted cohort.

Subgroup analyses
Patient with Child-Turcotte-Pugh class A cirrhosis

Figure 3A,B shows the comparison of decompensation
and overall survival between the viremic-HCC and SVR-
HCC groups among patients with CTP A cirrhosis at
Cancer  
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baseline. Similar to the primary analyses, IPTW analysis
demonstrated lower odds of decompensation at 6 months
(OR, 0.26; 95% CI, 0.06–0.78) and nonsignificant improvement in OS (HR, 0.61; 95% CI, 0.37–1.02) in the
SVR-HCC group compared to the viremic-HCC group.
5
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(A)

(B)

Figure 3. Forest plots (A) hepatic decompensation and (B) overall survival in subgroups analyses of patients with Child-Turcotte-
Pugh A cirrhosis, patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma, and patients receiving nonablative
hepatocellular carcinoma therapies.

Patients with BCLC stage B/C HCC

Viremic patients with prior exposure to DAAs

Figure 3A,B compares the incidence of hepatic decompensation and overall survival between the viremic-
HCC and SVR-HCC groups among those with BCLC
stage B or C HCC. IPTW analysis showed lower odds
of decompensation at 6 months in the SVR-
HCC
group (OR, 0.20; 95% CI, 0.04–0.65) as well as nonsignificant improvement in OS (OR, 0.72; 95% CI,
0.46–1.14).

A post hoc subgroup analysis comparing DAA-exposed
(n = 20) to DAA-naive (n = 411) viremic patients demonstrated similar OS between the two groups (log-rank
p = .61). Kaplan–Meier estimates for 2-year OS were
64% and 69% in patients treated and not treated with
DAAs before HCC diagnosis, respectively. The proportion of patients experiencing decompensation was 5%
versus 19% at 6 months (p = .13) and 24% versus 19%

6
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at 9 months (p = .63) for patients treated and not treated
with DAAs before HCC, respectively.
DISCUSSION
Treatment of HCV has been associated with benefits
across the spectrum of fibrosis stage and in patients with
a history of HCC after curative treatment. In this analysis, using a nationally representative multicenter cohort,
we showed SVR is associated with decreased risk of hepatic decompensation in patients with HCV-
related
HCC receiving noncurative therapies. This finding was
consistent in key subgroups of patients with CTP A cirrhosis and with intermediate or advanced (BCLC B/C)
stage HCC—patients with the highest competing risk
of HCC-related mortality. SVR was also associated with
improved survival, although the difference did not reach
statistical significance.
Our work builds on the growing body of evidence
showing the benefit of SVR in patients with cirrhosis by
preventing disease progression and reducing hepatic decompensation.17 Liver disease progression is known to
be a major driver of prognosis in compensated patients
with early-stage HCC, and our group has demonstrated
the safety and benefit of DAA therapy in patients who
have undergone curative treatment.9,10,18 In this study,
we similarly find patients with HCC who previously
achieved SVR have significantly reduced risk of hepatic
decompensation compared to those who remained viremic at time of HCC diagnosis. However, the reduced
risk of hepatic decompensation did not translate into
improved overall survival, likely due to the substantial competing risk of HCC mortality in this cohort.
Although the study was conducted after the availability of systemic therapies for HCC, the study period
preceded availability of currently available second-line
therapies as well as immune checkpoint inhibitors including atezolizumab-
bevacizumab—
that have significantly improved prognosis for patients undergoing
noncurative therapies.14 As median survival for patients
with BCLC B and C disease extends from 1 to 2 years
to 2–3 years, preservation of liver function will likely
become increasingly beneficial.19 Preservation of liver
function may also be critical to allow sequential therapies, including second-and potentially even third-line
systemic therapy options in some patients. Although
further data are needed in HCC patients undergoing
treatment in this contemporary therapeutic landscape,
our study suggests patients with HCC may benefit from
DAA treatment in the interim. Only 27.3% of patients
Cancer  
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in the viremic cohort were treated with DAA therapy
on follow-up, highlighting the wide variance in practice
in treatment of HCV.
Decisions regarding the benefit of HCV treatment in patients with active HCC would not only
need to consider potential OS benefits of SVR but also
other factors such as impact on quality of life, likelihood of SVR, and costs. Although several studies have
demonstrated that patients with HCV who achieve
SVR, including those with cirrhosis, have improved
quality of life, it is unknown if this benefit would be
observed in patients with HCC who can have other
drivers for impaired quality of life.20 Second, in this
study, we compared patients with post-SVR de novo
HCC to those with active viremia at HCC diagnosis;
however, several studies have demonstrated patients
with active HCC have reduced SVR rates compared to
non-HCC patients.21 Therefore, our study mirrored a
per-protocol analysis of HCV treatment benefit, rather
than intention-to-treat analysis. Finally, DAA therapy
has been shown to be cost-effective in patients with
HCV but HCC-specific studies should be performed,
considering the above factors.22
Our study has many strengths and weaknesses
that warrant further attention. The data collected were
retrospective, allowing for ascertainment bias in key
outcome variables such as hepatic decompensation or
overall survival. All included sites are tertiary referral
centers with high levels of patient retention and ability
to collect data from connected referral facilities, which
minimizes the risk of this bias. Unmeasured confounding is a well-described limitation of retrospective analyses; however, we were able to reliably collect data on
all known mediators of hepatic decompensation and
overall survival for the purposes of this analysis, minimizing this risk. Third, SVR occurred before diagnosis
of HCC, so the estimated benefits of HCV treatment
and/or achieving SVR in patients with active HCC
may be overestimated. Finally, there were inherent
group differences in baseline characteristics between
viremic-HCC and SVR-HCC patients; however, we attempted to balance known and measurable confounders through IPTW analyses. All known mediators of
decompensation were equally balanced between the
groups in the IPTW analyses, although there is still potential for selection bias and unmeasured confounders
that may have impacted our results. These limitations
were judged to be outweighed by the study’s notable
strengths, including its multicenter design with a large
cohort of patients, rigorous statistical analysis plan and
7
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consistent results across key subgroups. These data are
likely the most robust evidence for the benefits of SVR
in this population outside of a prospective randomized
trial for DAA treatment in this population.
In conclusion, we have shown the benefits associated with SVR in patients undergoing noncurative therapies for HCV in a large multicenter analysis. Although
the impact on subsequent hepatic decompensation were
most profound, there was also numerical improvement in
survival that may be evident in contemporary practice as
more efficacious systemic therapies for HCC are administered. Although the benefit of HCV treatment in patients
with active HCC has yet to be described, these data provide rationale for consideration of HCV treatment with
DAAs to induce SVR for all patients with HCC who are
eligible for therapy.
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